secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dare Bioscience, Inc. (DARE)
CIK:        0001401914
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0001641172-25-023971
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Daré Bioscience Q2 2025: Cash $5.0M, Sildenafil Cream launch on track for Q4 2025, Ovaprene DSMB positive
--------------------------------------------------------------------------------

- Cash of $5.0M at June 30; working capital deficit $12.6M; raised ~$17.6M net from ATM and $6M grant post-quarter.
- G&A $2.4M, R&D $1.4M (down 71% YoY) reflecting increased contra R&D from grants.
- DARE to PLAY Sildenafil Cream on track for Q4 2025 launch via 503B compounding, targeting near-term revenue.
- Ovaprene Phase 3 DSMB recommended continuation no new safety concerns; interim pregnancy rate consistent.
- DARE-HRT1 monthly ring pursuing 503B compounding for late 2026 alongside FDA pathway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401914/000164117225023971/0001641172-25-023971-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401914/000164117225023971/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-023971

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer